CD274 and neoplasm: In combination with chemotherapy, tislelizumab significantly improved OS when used in the frontline treatment of patients with PD-L1-positive (PD-L1 score ≥ 5% of tumor cells) locally advanced, unresectable, or metastatic gastric or GEJ adenocarcinoma (mOS 17.2 vs. 12.6 months; HR 0.74; 95% CI 0.59–0.94).